The role of tumour–stromal interactions in modifying drug response: challenges and opportunities

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nature reviews. Drug discovery

• Publication date

  2013-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrd3870PMID 23449307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer

  2013cited by this paper
• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

  2012cited by this paper
• Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

  2012cited by this paper
• Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukemia

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

  2012cited by this paper
• Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

  2012cited by this paper
• Translational approaches targeting the p53 pathway for anti‐cancer therapy

  2012cited by this paper
• Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.

  2012cited by this paper
• Lapatinib and Obatoclax Kill Tumor Cells through Blockade of ERBB1/3/4 and through Inhibition of BCL-xL and MCL-1

  2012cited by this paper
• Bone Marrow Stromal Cells Modulate Mouse ENT1 Activity and Protect Leukemia Cells from Cytarabine Induced Apoptosis

  2012cited by this paper
• Current advances in humanized mouse models

  2012cited by this paper
• Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

  2012cited by this paper
• The diverse and complex roles of NF-κB subunits in cancer

  2012cited by this paper
• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

  2012cited by this paper
• Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer.

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates.

  2012cited by this paper
• Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.

  2012cited by this paper
• New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance.

  2012cited by this paper
• Systematic identification of genomic markers of drug sensitivity in cancer cells

  2012cited by this paper
• Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?

  2012cited by this paper
• Recent advances in non-small cell lung cancer biology and clinical management.

  2012cited by this paper
• Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

  2012cited by this paper
• Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts

  2012cited by this paper
• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma.

  2012cited by this paper
• Functional genomics identifies therapeutic targets for MYC-driven cancer

  2012cited by this paper
• Paraneoplastic thrombocytosis in ovarian cancer.

  2012cited by this paper
• The metastatic niche and stromal progression

  2012cited by this paper
• Modeling and predicting clinical efficacy for drugs targeting the tumor milieu

  2012cited by this paper
• Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.

  2012cited by this paper
• Drug resistance and cellular adaptation to tumor acidic pH microenvironment.

  2011cited by this paper
• Fibroblasts contribute to melanoma tumor growth and drug resistance.

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.

  2011cited by this paper
• Immune microenvironments in solid tumors: new targets for therapy.

  2011cited by this paper
• Bone Marrow Stroma – Secreted Cytokines Protect JAK2 V617F -Mutated Cells from the Effects of a JAK2 Inhibitor

  2011cited by this paper
• Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis.

  2011cited by this paper
• Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

  2011cited by this paper
• Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

  2011cited by this paper
• Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment

  2011cited by this paper
• Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer

  2011cited by this paper
• Tumor metastasis: molecular insights and evolving paradigms.

  2011cited by this paper
• Genomically humanized mice: technologies and promises

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype

  2011cited by this paper
• Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.

  2011cited by this paper
• Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.

  2011cited by this paper
• The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment.

  2011cited by this paper
• Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation

  2011cited by this paper
• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

  2011cited by this paper
• Antibodies in oncology.

  2011cited by this paper
• Mouse models of advanced spontaneous metastasis for experimental therapeutics

  2011cited by this paper
• Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression

  2011cited by this paper
• Immune parameters affecting the efficacy of chemotherapeutic regimens

  2011cited by this paper
• Histamine restricts cancer: nothing to sneeze at

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• The microenvironment in breast cancer progression: biology and implications for treatment

  2011cited by this paper
• RAS oncogenes: weaving a tumorigenic web

  2011cited by this paper
• Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• New druggable targets in the Ras pathway?

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity

  2010cited by this paper
• The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.

  2010cited by this paper
• Effects of bone marrow stromal cells and umbilical cord blood-derived stromal cells on daunorubicin-resistant residual Jurkat cells.

  2010cited by this paper
• Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment

  2010cited by this paper
• Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

  2010cited by this paper
• Cancer esearch apeutics , Targets , and Chemical Biology textual Synthetic Lethality of Cancer Cell Kill Based R he Tumor Microenvironment

  2010cited by this paper
• Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

  2010cited by this paper
• Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

  2010cited by this paper
• Does tumour dormancy offer a therapeutic target?

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• Examining the metastatic niche: targeting the microenvironment.

  2010cited by this paper
• Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity

  2010cited by this paper
• Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of β1-integrin in K562 chronic myelogenous leukemia cell line

  2010cited by this paper
• Cancer and Inflammation: Promise for Biologic Therapy

  2010cited by this paper
• Third-generation tyrosine kinase inhibitors and beyond.

  2010cited by this paper
• How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.

  2009cited by this paper
• T cell activation.

  2009cited by this paper
• In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465

  2009cited by this paper
• Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model

  2009cited by this paper
• Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.

  2009cited by this paper
• Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation

  2009cited by this paper
• Revisiting the seed and soil in cancer metastasis.

  2009cited by this paper
• Transcription: Reaching a consensus

  2009cited by this paper
• Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

  2008cited by this paper
• AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

  2008cited by this paper
• Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers

  2008cited by this paper
• Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival

  2008cited by this paper
• Integrins: the keys to unlocking angiogenesis.

  2008cited by this paper
• Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.

  2008cited by this paper
• The anticancer immune response: indispensable for therapeutic success?

  2008cited by this paper
• Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine

  2008cited by this paper
• MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment

  2008cited by this paper

• Construction and immunotherapy application of lung cancer organoids.

  2026cites this paper
• Microbiota in cancer: current understandings and future perspectives

  2026cites this paper
• Cancer-associated fibroblasts drive metabolic heterogeneity in colorectal cancer cells: predictions from metabolic modeling.

  2026cites this paper
• A Robust Marine Collagen Peptide–Agarose 3D Culture System for In Vitro Modeling of Hepatocellular Carcinoma and Anti-Cancer Therapeutic Development

  2025cites this paper
• Challenges in the preclinical design and assessment of CAR-T cells

  2025cites this paper
• 3D Bioprinting for Engineering Organoids and Organ‐on‐a‐Chip: Developments and Applications

  2025cites this paper
• Cancer-associated fibroblasts drive metabolic heterogeneity in KRAS-mutant colorectal cancer cells

  2025cites this paper
• Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.

  2025cites this paper
• A fully human In-vitro model for bone metastasis: potential of electrospun scaffold as alternative to biological materials for osteoblast/osteoclast differentiation

  2025cites this paper
• The Role of Exosomes in Cancer Progression and Therapy

  2025cites this paper
• Lego‐Inspired Splicing of Modularized Vascular Channels

  2025cites this paper
• Screening of patient-derived organoids identifies mitophagy as a cell-intrinsic vulnerability in colorectal cancer during statin treatment

  2025cites this paper
• Engineering human endometrial model systems in reproductive health and disease

  2025cites this paper
• Advancing In Vitro Tools for Oncologic Research in Cats and Dogs

  2025cites this paper
• Connexin 43 inhibitors reduce cell viability in glioblastoma and astrocyte co-culture systems

  2025cites this paper
• [High expression of DTX2 promotes proliferation, invasion and epithelial-mesenchymal transition of oxaliplatin-resistant colorectal cancer cells].

  2025cites this paper
• A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

  2025cites this paper
• Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication

  2025cites this paper
• Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma.

  2025cites this paper
• CAFs exosomal miR-21-5p suppresses ferroptosis and promotes proliferation and migration in osteosarcoma

  2025cites this paper
• USP10 promotes cell proliferation and gemcitabine resistance in pancreatic cancer by the regulation of IGF2BP3-STEAP3

  2025cites this paper
• Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma

  2025cites this paper
• Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy

  2025cites this paper
• Synergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models

  2025cites this paper
• Exploring the Complexity of Cutaneous Squamous CellCarcinoma Microenvironment: Focus on Immune Cell Roles by Novel 3D In Vitro Models

  2025cites this paper
• Advancements in Metal and Metal Oxide Nanoparticles for Targeted Cancer Therapy and Imaging: Mechanisms, Applications, and Safety Concerns

  2025cites this paper
• Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges

  2024cites this paper
• Construction of tumor organoids and their application to cancer research and therapy

  2024cites this paper
• Improving tumor microenvironment assessment in chip systems through next-generation technology integration

  2024cites this paper
• Interactions between cancer and stroma mediated by extracellular vesicles

  2024cites this paper
• The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance.

  2024cites this paper
• Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions

  2024cites this paper
• Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer

  2024cites this paper
• Investigation of the feasibility of NRAV as a biomarker for hepatocellular carcinoma

  2024cites this paper
• Basal-to-inflammatory transition and tumor resistance via crosstalk with a pro-inflammatory stromal niche

  2024influential citation
• Cancer‐associated fibroblasts mediate resistance to neoadjuvant therapy in breast cancer

  2024cites this paper
• The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies

  2024cites this paper
• The Crosstalk Analysis between mPSCs and Panc1 Cells Identifies CCN1 as a Positive Regulator of Gemcitabine Sensitivity in Pancreatic Cancer Cells

  2024cites this paper
• Fabrication of heterocellular spheroids with controllable core-shell structure using inertial focusing effect for scaffold-free 3D cell culture models

  2024cites this paper
• Microphysiological systems as models for immunologically ‘cold’ tumors

  2024cites this paper
• PTX Inhibits Migration and Inflammatory Mediators in MCF-7 Breast Cancer Cells

  2024cites this paper
• Identification of a Novel Mesenchymal Stem Cell–Related Signature for Predicting the Prognosis and Therapeutic Responses of Bladder Cancer

  2024cites this paper
• Role of vascular endothelium and exosomes in cancer progression and therapy (Review)

  2024cites this paper
• TSPAN8+ myofibroblastic cancer–associated fibroblasts promote chemoresistance in patients with breast cancer

  2024cites this paper
• Exploring tumor organoids for cancer treatment

  2024cites this paper
• Understanding therapeutic tolerance through a mathematical model of drug-induced resistance

  2024cites this paper
• Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo.

  2024cites this paper
• 3D stem-like spheroids-on-a-chip for personalized combinatorial drug testing in oral cancer

  2024cites this paper
• Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions.

  2024cites this paper
• Enhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma

  2023cites this paper
• A preclinical platform for assessing long-term drug efficacy exploiting mechanically tunable scaffolds colonized by a three-dimensional tumor microenvironment

  2023cites this paper
• Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer

  2023cites this paper
• The Three-Dimensional In Vitro Cell Culture Models in the Study of Oral Cancer Immune Microenvironment

  2023cites this paper
• Cancer 3D Models for Metallodrug Preclinical Testing

  2023cites this paper
• Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions

  2023cites this paper
• A Novel Humanized Immune Stroma PDX Cancer Model for Therapeutic Studies

  2023cites this paper
• Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance

  2023cites this paper
• Cancer drug sensitivity prediction from routine histology images

  2023cites this paper
• Preclinical Tumor Mouse Models for Studying Esophageal Cancer.

  2023cites this paper
• Transición epitelio – mesenquima y cáncer.

  2023cites this paper
• Breast cancer organoids and their applications for precision cancer immunotherapy

  2023cites this paper
• An osteosarcoma-on-a-chip model for studying osteosarcoma matrix-cell interactions and drug responses

  2023cites this paper
• 3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation

  2023cites this paper
• Tackling the tumor microenvironment – how can complex tumor models in vitro aid oncology drug development?

  2023cites this paper
• Controlling Cell Organization in 3D Coculture Spheroids Using DNA Interactions.

  2023cites this paper
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer

  2023cites this paper
• Tumour-stroma ratio (TSR) in breast cancer: comparison of scoring core biopsies versus resection specimens

  2023cites this paper
• A comprehensive survey into the role of exosomes in pancreatic cancer; from the origin of cancer to the progress and possibility of diagnosis and treatment.

  2023cites this paper
• 3D cancer models: One step closer to in vitro human studies

  2023cites this paper
• 3D bioprinting tumor models mimic the tumor microenvironment for drug screening.

  2023cites this paper
• Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2

  2023cites this paper
• LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling

  2023cites this paper
• PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer

  2023cites this paper
• Evaluation of the Effect of Fibroblasts on Melanoma Metastasis Using a Biomimetic Co-Culture Model.

  2023cites this paper
• Synergistic cancer immunotherapy utilizing programmed Salmonella typhimurium secreting heterologous flagellin B conjugated to interleukin-15 proteins.

  2023cites this paper
• Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology.

  2023cites this paper
• Functional biomaterials for biomimetic 3D in vitro tumor microenvironment modeling

  2023cites this paper
• Surface-Engineered Monocyte Immunotherapy Combined Graphene Quantum Dots Effective Against Solid Tumor Targets

  2023cites this paper
• Awareness of intratumoral bacteria and their potential application in cancer treatment

  2023influential citation
• Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias

  2023cites this paper
• In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III

  2023cites this paper
• Embryonated Chicken Tumor Xenografts Derived from Circulating Tumor Cells as a Relevant Model to Study Metastatic Dissemination: A Proof of Concept

  2022cites this paper
• Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer

  2022cites this paper
• Three-dimensional (3D) cell culture: a valuable step in advancing treatments for human hepatocellular carcinoma

  2022cites this paper
• IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

  2022cites this paper
• Targeting cancer drug resistance utilizing organoid technology.

  2022cites this paper
• Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities.

  2022cites this paper
• Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas

  2022cites this paper
• Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives

  2022cites this paper
• Organoid Models for Precision Cancer Immunotherapy

  2022cites this paper
• Association of the tissue infiltrated and peripheral blood immune cell subsets with response to radiotherapy for rectal cancer

  2022cites this paper
• Multicellular Modelling of Difficult-to-Treat Gastrointestinal Cancers: Current Possibilities and Challenges

  2022cites this paper
• Microtubular Assessment of C6 Rat Glioma Cell Spheroids Developed in Transparent Liquid Marbles or Hanging Drops

  2022cites this paper
• ABSTRACTS (BY NUMBER)

  2022cites this paper
• Penetrating Micelle for Reversing Immunosuppression and Drug Resistance in Pancreatic Cancer Treatment.

  2022cites this paper
• Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs.

  2022cites this paper
• Role of Tumour-Associated Macrophages in Colon Cancer Progression and Its Therapeutic Targeting

  2022cites this paper
• 5-Fluorouracil Treatment of CT26 Colon Cancer Is Compromised by Combined Therapy with IMMODIN

  2022cites this paper
• Liquid Biopsy for Monitoring EC Patients: Towards Personalized Treatment

  2022cites this paper
• The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy

  2022cites this paper